NCT03301220 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 194
- group Id
- BG002
- value
- 390
- units
- Participants
- groups
- description
- Participants in the active monitoring group did not receive any study medication but underwent disease evaluations for every 12 weeks until disease progression (PD) as those randomized to receive daratumumab.
- id
- BG000
- title
- Arm A: Active Monitoring (ACTM)
- description
- Participants received daratumumab 1800 milligrams (mg) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 units per milliliter (U/mL) as subcutaneous (SC) injection once every week (Q1W) (Days 1, 8, 15, and 22 of each week) in Cycles 1 and 2, every 2 weeks (Q2W) (Days 1 and 15) from Cycle 3 to Cycle 6, and thereafter every 4 weeks (Day 1) from Cycle 7 to Cycle 39, for a maximum of 36 months, or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment. In addition, disease evaluations were performed every 12 weeks until PD. Each treatment cycle was 28 days. After end of treatment, participants were followed up for safety until death, lost to follow up, consent withdrawal or study end, whichever occurred first (up to 8 years).
- id
- BG001
- title
- Arm B: Daratumumab SC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.76
- value
- 63.0
- group Id
- BG001
- spread
- 11.17
- value
- 61.9
- group Id
- BG002
- spread
- 10.97
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 202
- title
- Female
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 188
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 169
- group Id
- BG002
- value
- 345
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 162
- group Id
- BG001
- value
- 161
- group Id
- BG002
- value
- 323
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 19
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 16
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 57
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 9
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 15
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 11
- title
- Brazil
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 8
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Denmark
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 11
- title
- Greece
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 196
- group Id
- BG001
- value
- 194
- group Id
- BG002
- value
- 390
- units
- Participants
- groups
- description
- Participants in the active monitoring group did not receive any study medication but underwent disease evaluations for every 12 weeks until disease progression (PD) as those randomized to receive daratumumab.
- id
- BG000
- title
- Arm A: Active Monitoring (ACTM)
- description
- Participants received daratumumab 1800 milligrams (mg) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 units per milliliter (U/mL) as subcutaneous (SC) injection once every week (Q1W) (Days 1, 8, 15, and 22 of each week) in Cycles 1 and 2, every 2 weeks (Q2W) (Days 1 and 15) from Cycle 3 to Cycle 6, and thereafter every 4 weeks (Day 1) from Cycle 7 to Cycle 39, for a maximum of 36 months, or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment. In addition, disease evaluations were performed every 12 weeks until PD. Each treatment cycle was 28 days. After end of treatment, participants were followed up for safety until death, lost to follow up, consent withdrawal or study end, whichever occurred first (up to 8 years).
- id
- BG001
- title
- Arm B: Daratumumab SC
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 10.76
- value
- 63.0
- group Id
- BG001
- spread
- 11.17
- value
- 61.9
- group Id
- BG002
- spread
- 10.97
- value
- 62.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 103
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 202
- title
- Female
- measurements
- group Id
- BG000
- value
- 93
- group Id
- BG001
- value
- 95
- group Id
- BG002
- value
- 188
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 176
- group Id
- BG001
- value
- 169
- group Id
- BG002
- value
- 345
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 22
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 31
- title
- Asian
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 162
- group Id
- BG001
- value
- 161
- group Id
- BG002
- value
- 323
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 19
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 10
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 16
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 57
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 9
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 15
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 11
- title
- Brazil
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 8
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Denmark
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 11
- title
- Greece
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle